Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer

Simple Summary The claudin (CLDN) family, the backbone of tight junctions, consists of more than 20 members in humans, and exhibits distinct expression patterns in tissue- and cell-type-specific manners. Among the CLDN members, CLDN6 is primarily expressed in diverse embryonic epithelial cells. It is also aberrantly expressed in various types of cancers, but its significance remains obscure. In the present study, we generated a highly specific anti-human CLDN6 monoclonal antibody, and assessed the prognostic significance of aberrant CLDN6 expression in endometrial cancer tissues. This study indicates that high CLDN6 expression in endometrial cancer relates to several clinicopathological factors and is an independent prognostic factor. The established monoclonal antibody could be a valuable tool to evaluate CLDN6-expressing tumors. Abstract Background: Among the claudin (CLDN) family, CLDN6 exhibits aberrant expression in various cancers, but its biological relevance has not yet been established. We generated a monoclonal antibody (mAb) against human CLDN6 and verified its specificity. By immunohistochemical staining and semi-quantification, we evaluated the relationship between CLDN6 expression and clinicopathological parameters in tissues from 173 cases of endometrial cancer. Results: The established mAb selectively recognized CLDN6 protein. Ten of the 173 cases (5.8%) showed high CLDN6 expression (score 3+), whereas 19 (11.0%), 18 (10.4%) and 126 (72.4%) cases revealed low CLDN6 expression (score 2+, 1+ and 0, respectively). In addition, intratumor heterogeneity of CLDN6 expression was observed even in the cases with high CLDN6 expression. The 5-year survival rates in the high and low CLDN6 groups was approximately 30% and 90%, respectively. Among the clinicopathological factors, the high CLDN6 expression was significantly associated with surgical stage III/IV, histological type, histological grade 3, lymphovascular space involvement, lymph node metastasis and distant metastasis. Furthermore, the high CLDN6 expression was an independent prognostic marker for overall survival of endometrial cancer patients (hazard ratio 3.50, p = 0.014). Conclusions: It can be concluded that aberrant CLDN6 expression is useful to predict poor outcome for endometrial cancer and might be a promising therapeutic target.

[1]  Oliver J. Klein,et al.  An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors , 2020, Science.

[2]  N. Sawada,et al.  Cell adhesion signals regulate the nuclear receptor activity , 2019, Proceedings of the National Academy of Sciences.

[3]  D. Bell,et al.  Clinical actionability of molecular targets in endometrial cancer , 2019, Nature Reviews Cancer.

[4]  Jason Gertz,et al.  Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions , 2019, Hormones and Cancer.

[5]  M. Haris,et al.  Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk , 2019, Front. Physiol..

[6]  Xia Cao,et al.  Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B , 2018, OncoTargets and therapy.

[7]  H. Aburatani,et al.  Gastric Cancer With Primitive Enterocyte Phenotype: An Aggressive Subgroup of Intestinal-type Adenocarcinoma , 2017, The American journal of surgical pathology.

[8]  P. Siegel,et al.  The role of claudins in cancer metastasis , 2017, Oncogene.

[9]  M. Balda,et al.  Tight junctions: from simple barriers to multifunctional molecular gates , 2016, Nature Reviews Molecular Cell Biology.

[10]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[11]  K. Polyak,et al.  Tumorigenesis: it takes a village , 2015, Nature Reviews Cancer.

[12]  Tsuyoshi Saito,et al.  The Tight-Junction Protein Claudin-6 Induces Epithelial Differentiation from Mouse F9 and Embryonic Stem Cells , 2013, PloS one.

[13]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[14]  M. Fukayama,et al.  Distinct expression pattern of claudin‐6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas , 2012, Histopathology.

[15]  J. Biegel,et al.  Claudin-6 is a Nonspecific Marker for Malignant Rhabdoid and Other Pediatric Tumors , 2012, The American journal of surgical pathology.

[16]  E. Dejana,et al.  Adhesion molecule signalling: not always a sticky business , 2011, Nature Reviews Molecular Cell Biology.

[17]  Takashi Kojima,et al.  Transmembrane proteins of tight junctions. , 2008, Biochimica et biophysica acta.

[18]  R. Sherwood,et al.  Genetic targeting of the endoderm with claudin-6CreER , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  S. Tsukita,et al.  Claudins in occluding junctions of humans and flies. , 2006, Trends in cell biology.

[20]  C. V. Van Itallie,et al.  Claudins and epithelial paracellular transport. , 2006, Annual review of physiology.

[21]  M. Osanai,et al.  Behavior of tight-junction, adherens-junction and cell polarity proteins during HNF-4alpha-induced epithelial polarization. , 2005, Experimental cell research.

[22]  I. Wada,et al.  Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and -independent pathways. , 2003, Experimental cell research.

[23]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  M. Osanai,et al.  Hepatocyte nuclear factor (HNF)-4α triggers formation of functional tight junctions and establishment of polarized epithelial morphology in F9 embryonal carcinoma cells , 2003 .

[25]  T. Yamashita,et al.  Thr203 of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions. , 2003, Experimental cell research.

[26]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[27]  K. Turksen,et al.  Claudin‐6: A novel tight junction molecule is developmentally regulated in mouse embryonic epithelium , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[28]  M. Osanai,et al.  Retinoid X Receptor α and Retinoic Acid Receptor γ Mediate Expression of Genes Encoding Tight-Junction Proteins and Barrier Function in F9 Cells during Visceral Endodermal Differentiation , 2001 .

[29]  S. Tsukita,et al.  Endothelial Claudin , 1999, The Journal of cell biology.

[30]  S. Baker,et al.  Profile of Women 45 Years of Age and Younger With Endometrial Cancer , 1998, Obstetrics and gynecology.

[31]  I. Naito,et al.  A novel method of preparing rat-monoclonal antibody-producing hybridomas by using rat medial iliac lymph node cells. , 1995, Cell structure and function.

[32]  M. Brewer,et al.  Endometrial Cancer: Is This a New Disease? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[33]  M. Osanai,et al.  Claudins in cancer: bench to bedside , 2016, Pflügers Archiv - European Journal of Physiology.

[34]  S. Oliveira,et al.  Claudins: multifunctional players in epithelial tight junctions and their role in cancer , 2006, Cellular and Molecular Life Sciences.

[35]  W. Remmele,et al.  Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer , 2004, Virchows Archiv A.